Key result
The Total Thrombus Analysis System provided stable baseline coagulation measurements in healthy dogs and detected significant delays in atheroma chip occlusion time following in vitro dalteparin exposure.
Why the study?
Coagulation tests have been unable to reflect in vivo coagulation status in the same system, including platelet function, fibrin clot formation, and whole blood flow.
p-value: p=0.045
The T-TAS is a reliable microfluidic assay for evaluating blood coagulation and the effects of antithrombotic drugs in canine models.
T-TAS reproducibly detects antiplatelet and anticoagulant effects in healthy dogs; leaves open clinical utility pending validation in bleeding patients.
To date, coagulation tests are unable to reflect in vivo coagulation status in the same system, including platelet function, fibrin clot formation, and whole blood flow. The Total Thrombus Analysis System (T-TAS), which is a microfluidic assay that simulates conditions in vivo, measures whole blood flow at defined shear rates under conditions designed to assess platelet function (PL-chip) or coagulation and fibrin clot formation (AR-chip). The T-TAS records occlusion start time, occlusion time, and area under the curve. We evaluated this test in healthy control dogs. We also investigated the effect in vivo of acetylsalicylic acid (ASA), and the effect in vitro of an anticoagulation drug (dalteparin; low-molecular-weight heparin; LMWH). The CV of the AUC of both chips was good (CVs of 6.45% [PL] and 1.57% [AR]). The inhibition of platelet function by ASA was evident in the right-shift in the PL test pressure curve. The right-shift in the AR test pressure curves showed that the administration of LMWH inhibited both platelets and the coagulation cascade. The T-TAS may be useful in the evaluation of canine blood coagulation.
No takes yet. Share an insight, caveat, or question.
Iwanaga et al. (2021) studied Healthy (evaluation of blood clotting) (n=7). Acetylsalicylic acid (in vivo) and dalteparin (in vitro) vs. Pre-treatment baseline was evaluated on Atheroma chip occlusion time (AR-OT) following in vitro dalteparin administration (p=0.045). The Total Thrombus Analysis System provided stable baseline coagulation measurements in healthy dogs and detected significant delays in atheroma chip occlusion time following in vitro dalteparin exposure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: